Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Apr 14, 2017; 23(14): 2575-2584
Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2575
Table 1 Mean dose and duration of omeprazole administered orally and intravenously
OMECasesadministered dose (mg)
OME administration (No. of days)
Mean ± SD95%CIMaxMinMean ± SD95%CIMaxMin
Oral17260.0 ± 143.2127.6-392.454618211.0 ± 8.03.6-18.3287
IV247217.2 ± 184.8162.8-271.3940403.8 ± 3.02.9-4.6161
IV + Oral39406.2 ± 184.9264.1-548.475615113.7 ± 7.08.2-19.1287
Table 2 Differences in the clinicopathological characteristics in eligible omeprazole users and non-eligible omeprazole users
CharacteristicsTotalEOU
P value
NonYes
Sex
Male9046440.59
Female351619
Age (yr)
< 607337360.77
≥ 60522527
BMI
< 2510047530.25
≥ 25251510
Tumor size (cm)
≤ 34924250.95
3-6613031
≥ 61587
Tumor grade
12814140.23
2884642
3927
cTNM
II3922170.31
III864046
CEA (ng/mL)
< 56228340.47
≥ 5583028
CA19-9 (U/mL)
< 3510250520.72
≥ 3518810
TGR
03923160.25
11587
220128
324915
4271017
CRT efficacy
Poor7443310.02
Good511932
ypTNM
ypcr259160.34
I261610
II402020
III341717
Adjuvant CT
No219120.5
Yes1045351
Recurrence
No9246460.66
Yes331617
Table 3 Differences in clinicopathological characteristics of non-eligible omeprazole users and eligible omeprazole users
CharacteristicsTotalEOG
P value
NonYes
Sex
Male9071190.380
Female352510
Age(yr)
< 607358150.410
≥ 60523814
BMI
< 2510077230.920
≥ 2525194
Tumor size (cm)
≤ 34937120.940
3-6614714
≥ 615123
Tumor grade
1282260.960
2886721
3972
cTNM
II393090.980
III866620
CEA (ng/mL)
< 56245170.390
≥ 5584612
CA19-9 (U/mL)
< 3510276260.420
≥ 3518153
TGR
0393450.330
115114
220164
324177
427189
CRT efficacy
Poor7461130.072
Good513516
ypTNM
ypcr251690.380
I26215
II40319
III34286
Adjuvant CT
No211470.230
Yes1048222
Recurrence
No9766260.025
Yes28303
Table 4 Univariate analysis of impact of various characteristics on patient survival
CharacteristicsnDFS
P valueOS
P value
Mean (mo)13-yr25- yr2Mean (mo)13- yr25- yr2
Sex
Male9061.8 ± 25.981.1%74.4%0.80365.5 ± 22.284.4%79.9%0.855
Female3565.6 ± 24.682.9%76.9%69.5 ± 20.188.6%79.8%
Age (yr)
< 607363.3 ± 26.380.1%71.1%0.53368.4 ± 22.086.3%80.7%0.908
≥ 605262.4 ± 24.682.7%80.7%64.2 ± 21.584.6%78.7%
Tumor size (cm)
≤ 34862.5 ± 26.181.2%77.0%0.57165.0 ± 22.483.3%79.2%0.962
> 37763.2 ± 25.381.8%74.0%67.7 ± 21.687.0%80.3%
BMI
< 2510060.5 ± 26.877.0%69.9%0.02465.3 ± 22.782.0%76.9%0.050
≥ 252572.7 ± 16.696.0%96.0%72.1 ± 17.096.0%92.0%
Tumor grade
12864.7 ± 28.078.6%75.0%0.85269.4 ± 22.585.7%78.6%0.931
2, 39762.4 ± 25.082.5%75.2%65.6 ± 21.785.6%80.2%
cTNM
II3969.2 ± 23.287.2%84.6%0.06771.9 ± 18.892.3%87.2%0.137
III8660.0 ± 26.279.1%70.7%64.2 ± 22.882.6%76.4%
CEA (ng/mL)
< 56277.0 ± 4.169.2%69.2%0.78979.6 ± 3.780.6%73.9%0.384
≥ 55880.4 ± 4.382.8%74.0%86.1 ± 3.489.7%84.5%
CA19-9 (U/mL)
< 3510281.3 ± 3.183.3%75.4%0.17484.2 ± 2.786.3%80.2%0.597
≥ 351868.1 ± 9.272.2%66.7%78.3 ± 7.877.8%72.2%
CRT efficacy
Poor7460.7 ± 27.278.4%67.5%0.03166.2 ± 23.283.8%75.6%0.144
Good5166.1 ± 23.090.2%86.0%67.3 ± 19.988.2%86.1%
ypTNM
ypcr,I, II9166.1 ± 24.085.7%82.3%0.00568.5 ± 20.189.0%84.4%0.041
III3454.3 ± 28.070.6%55.6%61.6 ± 25.576.5%67.6%
Adjuvant CT
No2160.2 ± 31.571.4%71.4%0.38563.5 ± 26.576.2%66.3%0.229
Yes10463.5 ± 24.383.7%75.8%67.3 ± 20.887.5%82.7%
OME
Non- EOU6270.0 ± 25.885.5%75.6%0.65873.9 ± 21.990.3%82.0%0.754
EOU6355.9 ± 23.577.8%74.6%59.5 ± 19.582.5%77.6%
OME (200 mg)
Non-EOG9662.0 ± 28.277.1%69.6%0.03266.9 ± 24.182.3%76.9%0.092
EOG2965.9 ± 13.396.6%46.7%65.8 ± 12.096.6%89.5%
Table 5 Univariate Cox analysis of the impact of various characteristics on patient survival
CharacteristicsDFS
P valueOS
P value
HR95%CIHR95%CI
Sex
Male vs Female0.910.42-1.650.8000.930.41-2.090.860
Age (yr)
< 60 vs ≥ 600.800.40-1.620.5301.050.50-2.190.910
BMI
< 25 vs ≥ 250.220.05-0.930.0390.260.06-1.110.069
Tumor size (cm)
≤ 3 vs > 31.230.60-2.510.5700.980.46-2.080.960
Tumor grade
1 vs 2, 31.080.47-2.500.8500.960.41-2.260.930
cTNM
II vs III2.230.92-5.410.0751.960.80-4.800.144
CEA (ng/mL)
< 5 vs ≥ 50.910.46-1.810.7900.720.34-1.510.390
CA199 (U/mL)
< 35 vs ≥ 351.770.77-4.080.1801.300.50-3.400.600
CRT efficacy
Poor vs good0.430.19-0.950.0360.550.24-1.240.150
ypTNM
ypcr, I,II vs III1.611.14-2.270.0061.461.01-2.110.045
Adjuvant CT
Non vs yes0.690.30-1.600.3900.600.25-1.400.240
EOU
Non vs yes1.170.59-2.310.6601.130.54-2.370.750
EOG
Non vs yes0.300.90-0.970.0440.370.11-1.230.110